PTTG‐1 (Securin) immunoexpression in meningiomas correlates with tumor grade and proliferation rate: potential use as a diagnostic marker of malignancy. Issue 4 (25th March 2018)

• Record Type: Journal Article
• Authors: Iliadis, Alexandros; Virvili, Maria‐Aikaterini; Flaris, Nicolaos A.; Pervana, Stavroula; Pazarli, Elissabet; Tripsianis, Grigoris; Grigoriou, Maria E.; Efstratiou, Ioannis; Kanakis, Dimitrios N.
• Is Part Of: Apmis. Volume 126:Issue 4(2018)
• Page Start: 295
• Page End: 302
• Publication Date: 2018-03-25
• Subjects: Pituitary tumor transforming gene -- meningioma -- Ki‐67 -- mitotic index -- WHO grade; Pathology -- Periodicals; Microbiology -- Periodicals; Immunology -- Periodicals; 572
• DOI: 10.1111/apm.12825
• Languages: English
• ISSNs: 0903-4641

Abstract

Abstract : This study essentially aims to contribute to the immunohistochemical investigation of the use of pituitary tumor transforming gene (PTTG) as a marker of cell proliferation or advanced tumor grade in meningiomas of various WHO grades. In all, 51 cases were recovered in total, 21 Grade‐I, 23 Grade‐II and 7 Grade‐III meningiomas. Mitotic index (MI), Ki‐67/MiB‐1 positivity percentage and PTTG expression were analyzed in correlation to each other as well as to the tumor WHO grades. All three biomarkers showed a high diagnostic significance and a strong association with WHO grades. In comparison, PTTG expression was on a par with the other two indices, and performed very well regarding identification of advanced grade tumors. PTTG may be considered an important diagnostic tool and serve in the future as a novel prognosticator of the biological behavior of all grade meningiomas as well as a useful high‐risk patient selection tool.